<DOC>
	<DOCNO>NCT01508806</DOCNO>
	<brief_summary>This trial conduct Oceania . The aim trial ass whether dose adjustment require patient renal impairment investigate pharmacokinetics liraglutide subject various degree renal impairment .</brief_summary>
	<brief_title>Safety Tolerability Liraglutide Subjects With Impaired Kidney Function Subjects With Normal Kidney Function</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Subjects meeting predefined GFR ( glomerular filtration rate ) criterion ( estimate Cockcroft Gault formula ) renal function group Body Mass Index ( BMI ) maximum 40 kg/m^2 Known suspect allergy trial product ( ) relate product Renal transplant patient Haemodialysis patient Cardiac problem Uncontrolled treated/untreated hypertension History alcoholism drug abuse last 12 month Smoking 10 cigarette per day , equivalent tobacco product Habitual excessive consumption methylxanthinecontaining beverage food ( coffee , tea , soft drink cola , chocolate ) judge investigator Excessive consumption food deviate normal diet judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>